Single User License
INR 100155
Site License
INR 200310
Corporate User License
INR 300465

Service Tax Additional

select a format

Single User License
USD 1500
Site License
USD 3000
Corporate User License
USD 4500


Request a quote
Request a Customized research
Request for Sample Report

Recent Viewed Reports

Why Ken Reasearch?


While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"

Beta Pharma, Inc.-Product Pipeline Review-2015

Beta Pharma, Inc.-Product Pipeline Review-2015

  Request for Sample Report

Executive Summary

Beta Pharma, Inc.-Product Pipeline Review-2015


Global Markets Direct's, 'Beta Pharma, Inc.-Product Pipeline Review-2015', provides an overview of the Beta Pharma, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Beta Pharma, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of Beta Pharma, Inc. including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Beta Pharma, Inc.'s human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Beta Pharma, Inc.'s pipeline products

Reasons To Buy

Evaluate Beta Pharma, Inc.'s strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Beta Pharma, Inc. in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Beta Pharma, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Beta Pharma, Inc. and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Beta Pharma, Inc.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Beta Pharma, Inc. and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 3

Beta Pharma, Inc. Snapshot 4

Beta Pharma, Inc. Overview 4

Key Information 4

Key Facts 4

Beta Pharma, Inc.-Research and Development Overview 5

Key Therapeutic Areas 5

Beta Pharma, Inc.-Pipeline Review 7

Pipeline Products by Stage of Development 7

Pipeline Products-Monotherapy 8

Pipeline Products-Partnered Products 9

Partnered Products/Combination Treatment Modalities 10

Beta Pharma, Inc.-Pipeline Products Glance 11

Beta Pharma, Inc.-Clinical Stage Pipeline Products 11

Phase I Products/Combination Treatment Modalities 11

Beta Pharma, Inc.-Early Stage Pipeline Products 12

Preclinical Products/Combination Treatment Modalities 12

Discovery Products/Combination Treatment Modalities 13

Beta Pharma, Inc.-Drug Profiles 14

icotinib hydrochloride 14

Product Description 14

Mechanism of Action 14

R&D Progress 14

BPI-0403 15

Product Description 15

Mechanism of Action 15

R&D Progress 15

BPI-3119 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

BPI-5143 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

BPI-4039 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

Beta Pharma, Inc.-Pipeline Analysis 19

Beta Pharma, Inc.-Pipeline Products by Target 19

Beta Pharma, Inc.-Pipeline Products by Route of Administration 20

Beta Pharma, Inc.-Pipeline Products by Molecule Type 21

Beta Pharma, Inc.-Pipeline Products by Mechanism of Action 22

Beta Pharma, Inc.-Dormant Projects 23

Beta Pharma, Inc.-Locations And Subsidiaries 24

Head Office 24

Other Locations & Subsidiaries 24

Appendix 25

Methodology 25

Coverage 25

Secondary Research 25

Primary Research 25

Expert Panel Validation 25

Contact Us 25

Disclaimer 26

List of Tables

Beta Pharma, Inc., Key Information 4

Beta Pharma, Inc., Key Facts 4

Beta Pharma, Inc.-Pipeline by Indication, 2015 6

Beta Pharma, Inc.-Pipeline by Stage of Development, 2015 7

Beta Pharma, Inc.-Monotherapy Products in Pipeline, 2015 8

Beta Pharma, Inc.-Partnered Products in Pipeline, 2015 9

Beta Pharma, Inc.-Partnered Products/ Combination Treatment Modalities, 2015 10

Beta Pharma, Inc.-Phase I, 2015 11

Beta Pharma, Inc.-Preclinical, 2015 12

Beta Pharma, Inc.-Discovery, 2015 13

Beta Pharma, Inc.-Pipeline by Target, 2015 19

Beta Pharma, Inc.-Pipeline by Route of Administration, 2015 20

Beta Pharma, Inc.-Pipeline by Molecule Type, 2015 21

Beta Pharma, Inc.-Pipeline Products by Mechanism of Action, 2015 22

Beta Pharma, Inc.-Dormant Developmental Projects,2015 23

Beta Pharma, Inc., Subsidiaries 24

List of Figures

Beta Pharma, Inc.-Pipeline by Top 10 Indication, 2015 6

Beta Pharma, Inc.-Pipeline by Stage of Development, 2015 7

Beta Pharma, Inc.-Monotherapy Products in Pipeline, 2015 8

Beta Pharma, Inc.-Partnered Products in Pipeline, 2015 9

Beta Pharma, Inc.-Pipeline by Top 10 Target, 2015 19

Beta Pharma, Inc.-Pipeline Products by Top 10 Mechanism of Action, 2015 22

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@]

Current R&D Portfolio of Beta Pharma, Inc.; Beta Pharma, Inc. - Key Therapeutics; Beta Pharma, Inc. - Pipeline Overview and Promising Molecules; Beta Pharma, Inc. - News; Beta Pharma, Inc. - Latest Updates; Beta Pharma, Inc. - Pipeline; Beta Pharma, Inc. - Discontinued/Dormant Projects

Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204


Company Brochure

Engage with Us

query [@]